Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

PMI vs RDN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RDN Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

RDN Overall Winner 6-Pillar Tally: PMI 0 – 5 RDN (1 Tie) Matrix Metrics: PMI 2 – 8 RDN

As of Nov 19, 2026, Radian Group Inc. (RDN) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas RDN carries 34.9/100 (SELL) at $36.47 (6.9x Forward P/E, 45.4% operating margin).

  • Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. RDN 34.9/100 SELL), RDN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (45.4% vs. -248.1% operating margin) and revenue trajectory (+105.7% vs. +38.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PMI vs RDN
PMI NYSE American
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62
RDN NYSE Head-to-Head Winner
Radian Group Inc.
Surety Insurance
$36.47
-0.16% 1D
Market Cap $4.6B
TTM Revenue $1.97B
Forward P/E 6.9x
Beta / 30D Vol -0.07β · 26% Vol
Unified Composite Score
34.9 / 100 SELL
Tech 36.0 Fund 42.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 54.6 · SMA20: $36.29 · SMA50: $34.87

6-Pillar Scorecard Institutional Category Breakdown (PMI 0 – 5 RDN)

Columns: Metric · PMI · RDN
1. Valuation Multiples RDN
Forward P/E N/M 6.9x
Trailing P/E 2.9x 8.7x
PEG Ratio N/M 0.76x
EV / Revenue 3.2x 2.3x
2. Growth & Scale RDN
Revenue Growth (YoY) +38.6% +105.7%
Earnings Growth (YoY) +0.0% +18.4%
TTM Revenue (USD) $6.3M $1.97B
Market Cap $17.1M $4.6B
3. Profitability & Quality RDN
Gross Margin 18.6% 62.5%
Operating Margin -248.1% 45.4%
Net Profit Margin 0.0% 28.3%
Return on Equity (ROE) 0.0% 12.4%
4. Balance Sheet & Cash Flow RDN
Cash Generation (TTM) -$17M $947M EBITDA
Cash Flow Margin N/A 48.1% EBITDA Mgn
Net Cash / Leverage $3.2M Net Debt $35.78 Book/Sh · 12.4% ROE
Dividend Yield None (0.00%) 2.79%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 28.8% (5th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat RDN
OpEx & R&D Intensity N/A 17.1% of Rev ($337M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Medical Devices Operator Insurance - Specialty Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PMI (2) vs RDN (8)
Institutional Metric PMI RDN Criterion Row Edge
Market Capitalization
Scale
$17.1M $4.6B Larger Scale RDN
Trailing P/E Ratio
Valuation
2.9x 8.7x Lower Multiple PMI
Forward P/E Ratio
Valuation
N/M 6.9x Lower Multiple RDN
Revenue Growth (YoY)
Growth
+38.6% +105.7% Higher Growth RDN
Operating Margin (TTM)
Profitability
-248.1% 45.4% Higher Margin RDN
Net Profit Margin
Profitability
0.0% 28.3% Higher Margin RDN
Return on Equity (ROE)
Capital Efficiency
0.0% 12.4% Higher ROE RDN
52-Week Range Position
Momentum
34% ($0–$18) 56% ($31–$41) Stronger Trend RDN
Beta / 30D Volatility
Risk Regime
54.06β · 134% Vol -0.07β · 26% Vol Lower Realized Risk RDN
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 34.9 / 100 (SELL) Higher Composite PMI
Trailing 12M Revenue (USD)
Operating Scale
$6.3M $1.97B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.6% 62.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev 0.76x PEG · 2.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($3.2M Net Debt) $947M EBITDA ($35.78 Book/Sh · 12.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RDN +41.91 pp
PMI: -34.58% · RDN: +7.33%
3M Horizon PMI +96.59 pp
PMI: +96.26% · RDN: -0.33%
6M Horizon PMI +3441.29 pp
PMI: +3439.33% · RDN: -1.96%
1Y Horizon PMI +142.26 pp
PMI: +148.03% · RDN: +5.77%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PMI vs RDN. Trailing 12-month operating profitability (PMI -248.1% vs RDN 45.4%) and valuation multiples (PMI N/M vs RDN 6.9x Forward P/E) are benchmarked directly in Pillar 4 below.

PMI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.3M
Gross Margin18.6%
Op. Margin-248.1%
ROE / Fwd P/E0.0% · N/M
RDN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.97B
Gross Margin62.5%
Op. Margin45.4%
ROE / Fwd P/E12.4% · 6.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RDN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 28.8%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RDN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RDN Moat Profile High-Margin Pricing Power Moat
Insurance - Specialty Operator
Competes within the Insurance - Specialty value chain with $4.6B market capitalization and 45.4% operating margin.
OpEx & R&D Reinvestment 17.1% of Rev ($337M)
90D Engineering Disclosures 0 Published

Investor FAQ PMI vs RDN Key Questions & Quantitative Answers

As of Nov 19, 2026, Radian Group Inc. (RDN) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas RDN carries 34.9/100 (SELL) at $36.47 (6.9x Forward P/E, 45.4% operating margin). Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. RDN 34.9/100 SELL), RDN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (45.4% vs. -248.1% operating margin) and revenue trajectory (+105.7% vs. +38.6% YoY).

RDN leads the Growth & Scale pillar: PMI posts +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin), compared with RDN at +105.7% YoY revenue growth and +18.4% YoY earnings growth on $1.97B TTM revenue (62.5% gross margin, 45.4% operating margin). On trailing 12-month operating scale, PMI generates $6.3M in USD-normalized revenue versus $1.97B for RDN. In operating R&D and SG&A reinvestment, PMI deploys N/A (0 90-day corporate R&D disclosures) versus 17.1% of Rev ($337M) (0 disclosures) for RDN.

RDN screens cheaper on headline valuation multiples. PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin), whereas RDN trades at 6.9x Forward P/E, 8.7x Trailing P/E, 0.76x PEG, and 2.3x EV/Revenue (48.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PMI (0.0% ROE) versus RDN (12.4% ROE) capital efficiency.

In options market volatility and institutional positioning, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk). By comparison, RDN carries 28.8% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 26% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.